MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Tricida Book Value 2011-2026 | TCDA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 218 K | 109 M | 264 M | 195 M | 59.2 M | -47.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | -47.6 M | 96.5 M |
Quarterly Book Value Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -136 M | -111 M | -90.3 M | 218 K | 1.9 M | 34.9 M | 61.6 M | 109 M | 109 M | 109 M | 109 M | 264 M | 264 M | 264 M | 264 M | 195 M | 195 M | 195 M | 195 M | 59 M | 59 M | 59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | -136 M | 100 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.59 | 3.79 % | $ 10.3 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.32 | - | $ 86.3 M |  Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 35.2 | - | $ 1.29 B | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.71 B | $ 2.58 | - | $ 1.34 B | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.01 | - | $ 410 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
-82 M | $ 4.99 | - | $ 1.82 B | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.2 | - | $ 1.07 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.43 | - | $ 286 M | USA |
 |
Perrigo Company plc
PRGO
|
2.94 B | $ 9.64 | - | $ 1.34 B | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 1.03 | - | $ 24 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 6.68 | - | $ 585 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.37 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.34 | - | $ 2.9 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.66 | - | $ 4.12 B | Canada |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.1 | - | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.34 | - | $ 402 M | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.9 | - | $ 44.9 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 13.36 | - | $ 16 B | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.77 | - | $ 3.32 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.41 | - | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 0.96 | - | $ 103 M | Canada |
 |
Assertio Holdings
ASRT
|
94 M | $ 16.51 | - | $ 106 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.29 | - | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |